Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Tingbo Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3262-2587; OpenAlex author ID A5007502535, A5101430799. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 5 papers · 2024: 1 paper · 2025: 8 papers · 2026: 3 papers

Papers 22

  1. Preoperative prediction of early recurrence in pancreatic cancer: A novel clinical-radiomics model. Co-author DOI 10.1002/ijc.70142↗
  2. Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. Co-author DOI 10.1038/s44321-026-00506-5↗
  3. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Last author DOI 10.1200/jco-26-01393↗
  4. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Co-author DOI 10.1002/cac2.70038↗
  5. Integrating Body Composition and Nutritional Indices: A Novel Prognostic Tool for Survival in Pancreatic Cancer. Last author DOI 10.1002/jcsm.70006↗
  6. [18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Last author DOI 10.1007/s00259-025-07271-6↗
  7. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Last author DOI 10.1016/j.canlet.2025.217658↗
  8. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Last author DOI 10.1016/j.ccell.2025.09.009↗
  9. STING-activating pyroptotic nanoparticles for in situ pancreatic cancer vaccination and immunotherapy. Last author DOI 10.1016/j.scib.2025.04.015↗
  10. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Last author DOI 10.1097/sla.0000000000006719↗
  11. Correction: Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. Last author DOI 10.1186/s12951-024-03033-y↗
  12. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Last author DOI 10.1038/s41420-024-01862-2↗
  13. An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer. Last author DOI 10.1002/advs.202206756↗
  14. Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.bioactmat.2022.05.022↗
  15. NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2023.216285↗
  16. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation. Last author DOI 10.1016/j.pan.2023.10.021↗
  17. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Co-author DOI 10.1245/s10434-023-13383-w↗
  18. Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Last author DOI 10.1002/advs.202202914↗
  19. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
  20. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1016/j.hpb.2020.01.001↗
  21. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0486-z↗
  22. Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Last author DOI 10.1016/j.pan.2014.06.008↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 5 shared papers, 2020–2025 · strength 0.96
  2. Shiyi Shao · 4 shared papers, 2022–2025 · strength 0.85
  3. Guoliang Qiao · 4 shared papers, 2025–2026 · strength 0.84
  4. Xiang Li Ma · 4 shared papers, 2023–2025 · strength 0.77
  5. Risheng Que · 4 shared papers, 2023–2026 · strength 0.76
  6. Qida Hu · 4 shared papers, 2014–2025 · strength 0.73
  7. Kang Sun · 3 shared papers, 2024–2025 · strength 0.68
  8. Tianan Jiang · 3 shared papers, 2025–2026 · strength 0.61
  9. Qi Zhang · 3 shared papers, 2020–2026 · strength 0.54
  10. Xueli Bai · 3 shared papers, 2014–2026 · strength 0.49
  11. Yiting Xu · 2 shared papers, 2025–2026 · strength 0.47
  12. Qi Zhang · 2 shared papers, 2025–2026 · strength 0.47
  13. Lihong He · 2 shared papers, 2024–2025 · strength 0.46
  14. Xiaozhen Zhang · 2 shared papers, 2025–2026 · strength 0.44
  15. Meng Wang · 2 shared papers, 2022–2025 · strength 0.43
  16. Qi Zhang · 2 shared papers, 2025 · strength 0.39
  17. Yiwen Chen · 2 shared papers, 2020–2025 · strength 0.35
  18. Xiang Li · 2 shared papers, 2020–2025 · strength 0.34
  19. Qihan Fu · 2 shared papers, 2020–2023 · strength 0.28
  20. Ningna Weng · 1 shared paper, 2026 · strength 0.26
  21. Zhe Zhang · 1 shared paper, 2026 · strength 0.26
  22. Yi Zang · 1 shared paper, 2026 · strength 0.26
  23. Xu Han · 1 shared paper, 2026 · strength 0.24
  24. Qingbo Meng · 1 shared paper, 2024 · strength 0.24
  25. Xiazhen Yu · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.